Biomarin Pharma (NASDAQ: BMRN) exceeded analysts’ estimates in its first-quarter results. The company reported an EPS of $0.71, $0.39 higher than the consensus estimate of $0.32. Revenue for the quarter came in at $649 million, in line with the estimate of $649.27 million. Biomarin Pharma also raised its guidance for fiscal year 2024, with EPS expected to be between $2.75 and $2.95 and revenue projected to range from $2.70 billion to $2.80 billion.